All In Biotech

Drug Trial Radar · NCT05104567

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Advanced and Metastatic Gastrointestinal Cancer

Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

138

Actual

Start

Dec 9, 2021

Primary completion

Jul 26, 2023

Study completion Sep 9, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Nov 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years and older with advanced and metastatic gastrointestinal cancer. This study is structured as a master protocol for the investigation of SAR444245 with other anticancer therapies. Sub study 01 - Cohort A aims to establish proof-of-concept that combining the non-alpha-IL2 SAR444245 with the anti-PD1 antibody pembrolizumab will result in a significant increase in the percentage of patients experiencing an objective response in the setting of advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC). Sub study 02 - Cohort B1, B2 and B3 would focus on non MSI-H tumors with a large unmet need to establish proof-of-concept that combining the non-alpha-IL2 SAR444245 with the anti-PD1 antibody pembrolizumab will result in a significant increase in the percentage of patients experiencing an objective response in the setting of advanced unresectable or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma (GC/GEJ), especially with low PD-L1 expression or after progression on prior PD1/PD-L1-based regimens. Sub study 03 - Cohort C aims to establish proof-of-concept that combining the non-alpha-IL2 SAR444245 with the anti-PD1 antibody pembrolizumab will result in a significant increase in the percentage of patients experiencing an objective response in participants with advanced unresectable or metastatic HCC who relapsed on prior PD1/PD-L1-based regimens. Sub study 04 - Cohort D1 and D2 aims to establish proof-of-concept that combining the non-alpha-IL2 SAR444245 with either the anti-PD1 antibody pembrolizumab or with the anti-EGFR IgG1 antibody cetuximab will result in a significant increase in the percentage of patients experiencing an objective response in the setting of advanced unresectable or metastatic colorectal cancer (mCRC).

Conditions

  • Oesophageal Squamous Cell Carcinoma
  • Gastric Cancer
  • Hepatocellular Carcinoma
  • Colorectal Cancer
  • Oesophageal Adenocarcinoma

Interventions

  • THOR-707Drug

    Solution for infusion: intravenous infusion

  • PembrolizumabDrug

    Solution for infusion: intravenous infusion

  • CetuximabDrug

    Solution for infusion: intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A: Objective Response Rate (ORR)Time frame: From first dose of study treatment administration (Day 1) up to maximum exposure of study treatment; approximately 8 months
  2. Cohorts B1, B2 and B3: Objective Response RateTime frame: From first dose of study treatment administration (Day 1) up to maximum exposure of study treatment; approximately 25 months
  3. Cohort C: Objective Response RateTime frame: From first dose of study treatment administration (Day 1) up to maximum exposure of study treatment; approximately 20 months
  4. Cohorts D1 and D2: Objective Response RateTime frame: From first dose of study treatment administration (Day 1) up to maximum exposure of study treatment; approximately 8 months

Locations

29 sites in 9 countries. Site status is shown where the registry gives one.

  • City of Hope Site Number : 8400007

    Duarte, California

  • AdventHealth Orlando Site Number : 8400005

    Orlando, Florida

  • Seattle Cancer Care Alliance Site Number : 8400009

    Seattle, Washington

  • Investigational Site Number : 0560002

    Brussels, Belgium

  • Investigational Site Number : 0560003

    Edegem, Belgium

  • Investigational Site Number : 0560001

    Leuven, Belgium

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1560002

    Wuhan, China

  • Investigational Site Number : 2500004

    Bordeaux, France

  • Investigational Site Number : 2500006

    Brest, France

  • Investigational Site Number : 2500002

    Paris, France

  • Investigational Site Number : 2500005

    Poitiers, France

  • Investigational Site Number : 2500001

    Villejuif, France

  • Investigational Site Number : 3800003

    Milan, Italy

  • Investigational Site Number : 3800002

    Milan, Italy

  • Investigational Site Number : 3800001

    Rozzano, Lombardy, Italy

  • Investigational Site Number : 5280001

    Amsterdam, Netherlands

  • Investigational Site Number : 5280003

    Rotterdam, Netherlands

  • Investigational Site Number : 4100002

    Seoul, Seoul-teukbyeolsi, South Korea

  • Investigational Site Number : 4100004

    Seoul, Seoul-teukbyeolsi, South Korea

  • Investigational Site Number : 4100001

    Seoul, Seoul-teukbyeolsi, South Korea

  • Investigational Site Number : 4100003

    Seoul, Seoul-teukbyeolsi, South Korea

  • Investigational Site Number : 7240002

    Barcelona, Barcelona [Barcelona], Spain

  • Investigational Site Number : 7240006

    Barcelona, Barcelona [Barcelona], Spain

  • Investigational Site Number : 7240005

    Santander, Cantabria, Spain

  • Investigational Site Number : 7240101

    Madrid, Madrid, Comunidad de, Spain

  • Investigational Site Number : 7240003

    Madrid / Madrid, Madrid, Comunidad de, Spain

  • Investigational Site Number : 7240004

    Madrid / Madrid, Madrid, Comunidad de, Spain

  • Investigational Site Number : 7240001

    Pamplona, Navarre, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.